

Financial news for CYTR dated on 2019-11-18: Stocks That Hit 52-Week Lows On Monday

Financial news for CYTR dated on 2019-10-25: Stocks That Hit 52-Week Lows On Friday

Financial news for CYTR dated on 2019-10-14: Stocks That Hit 52-Week Lows On Monday

Financial news for CYTR dated on 2019-10-02: Stocks That Hit 52-Week Lows On Wednesday

Financial news for CYTR dated on 2019-10-01: Stocks That Hit 52-Week Lows On Tuesday

Financial news for CYTR dated on 2019-08-16: Stocks That Hit 52-Week Lows On Friday

Financial news for CYTR dated on 2019-08-09: CytRx Q2 EPS \$(0.04) Up From \$(0.1) YoY

Financial news for CYTR dated on 2019-07-22: CytRx Corporation Highlights Arimoclomol Licensee Orphazyme A/S Completes Enrollment In Its Phase 3 Clinical Trial Of Arimoclomol In Amyotrophic Lateral Sclerosis

Financial news for CYTR dated on 2019-06-04: Shares of several healthcare companies are trading higher with the overall US market. Recent comments out of China and Mexico has renewed trade optimism and lifted economic outlook.

Financial news for CYTR dated on 2019-06-04: The Daily Biotech Pulse: ASCO Presentations From Roche, Celgene & More, Edwards Recommends Rejection Of Mini-Tender Offer

Financial news for CYTR dated on 2019-05-31: CytRx shares are trading lower after the company announced it will commence trading on the OTCQB Venture Market.

Financial news for CYTR dated on 2019-05-31: CytRx Corporation To Commence Trading On OTCQB Venture Market

Financial news for CYTR dated on 2019-05-15: CytRx Q1 EPS \$(0.04) Beats \$(0.06) Estimate

Financial news for CYTR dated on 2019-05-08: CytRx Highlights Issuance Of Patent For Aldoxorubicin In The Treatment Of Brain Cancer

Financial news for CYTR dated on 2019-05-02: CytRx Corporation Highlights Arimoclomol Clinical Milestone Guidance Provided By Licensee Orphazyme A/S

Financial news for CYTR dated on 2019-04-29: CytRx shares are trading higher after the company announced that its licensee, Orphazyme, has completed enrollment in its Phase 2/3 clinical trial of arimoclomol for the treatment of sporadic inclusion body myositis.

Financial news for CYTR dated on 2019-04-29: CytRx Corporation Highlights Enrollment Completion In Phase 2/3 Clinical Trial Of Sporadic Inclusion Body Myositis Conducted By Arimoclomol Licensee Orphazyme A/S

Financial news for CYTR dated on 2019-03-29: CytRx FY18 EPS \$(0.41) vs \$(1.46) In FY17

Financial news for CYTR dated on 2019-02-06: UPDATE: CytRx Says 'Eligible to Receive up to \$120M in Future Milestones, Plus Royalties, From Arimoclomol Licensing Agreement'

Financial news for CYTR dated on 2019-02-06: UPDATE: CytRx Says Orphazyme to Engage with FDA and EMA on Path to Approval While Preparing for Filing

Financial news for CYTR dated on 2019-02-06: CytRx Highlights Results From Full Data Set of Phase 2/3 Clinical Trial in Niemann Pick Disease Type C (NPC) Conducted by Arimoclomol Licensee Orphazyme A/S

Financial news for CYTR dated on 2018-12-21: CytRx Corporation Subsidiary Centurion BioPharma Announces Conclusion Of Pre-Clinical Phase For Its Albumin Binding Ultra High Potency LADR Drug Candidates And Accompanying Companion Diagnostic

Financial news for CYTR dated on 2018-12-20: Stocks Which Set New 52-Week Low Yesterday, Tues., Dec. 20, 2018

Financial news for CYTR dated on 2018-12-19: The Daily Biotech Pulse: Pfizer-Glaxo Set Up Consumer Health Care Venture, New Patent For Adamas

Financial news for CYTR dated on 2018-12-18: The Daily Biotech Pulse: Puma Aces Late-Stage Trial, Chinese Cheer For FibroGen, J&J \$5B Buyback Plan

Financial news for CYTR dated on 2018-12-14: Stocks Which Set New 52-Week Low

Yesterday, Thurs., Dec. 13, 2018

Financial news for CYTR dated on 2018-12-04: Stocks Which Set New 52-Week Low Yesterday, Mon., Dec. 3, 2018

Financial news for CYTR dated on 2018-11-28: Stocks Which Set New 52-Week Low Yesterday Tues., Nov. 27, 2018

Financial news for CYTR dated on 2018-11-19: Stocks Which Set New 52-Week Lows Fri., Nov. 16, 2018

Financial news for CYTR dated on 2018-11-02: CytRx Q3 EPS \$(0.10) Up From \$(0.19) YoY, Licensing Revenue \$250K

Financial news for CYTR dated on 2018-11-02: The Daily Biotech Pulse: Illumina Snaps Up Pacific Bioscience, Thumbs Down For Alkermes Depressive Disorder Drug

Financial news for CYTR dated on 2018-10-25: The Daily Biotech Pulse: AbbVie Takes Full Control Of Cystic Fibrosis Program, Amgen Slashes Cholesterol Drug Price

Financial news for CYTR dated on 2018-10-24: Stocks Which Set New 52-Week Low Yesterday, October 23rd

Financial news for CYTR dated on 2018-10-24: The Daily Biotech Pulse: Illumina's Strong Q3, Celgene's Positive Cancer Drug Trial, Proteostasis Offering

Financial news for CYTR dated on 2018-10-23: Stocks Which Set New 52-Week Low Yesterday, October 22nd

Financial news for CYTR dated on 2018-10-23: The Daily Biotech Pulse: Regulus Soars On Positive Pre-Clinical Data, Biogen Earnings, Proteostasis And Eiger to Offer Shares

Financial news for CYTR dated on 2018-10-17: The Daily Biotech Pulse: Eiger's Lymphoedema Drug Study Fails, Roche's Sales Rise

Financial news for CYTR dated on 2018-10-12: Stocks Which Set New 52-Week Low Yesterday, October 11th

Financial news for CYTR dated on 2018-10-12: The Daily Biotech Pulse: FDA Thumbs Down For Trevena, Corium To Go Private, Immune Design Discontinues Cancer Vaccine Program

Financial news for CYTR dated on 2018-10-11: Stocks Which Set New 52-Week Low Yesterday, October 10th

Financial news for CYTR dated on 2018-10-11: The Daily Biotech Pulse: Clinical Hold Lifted Off Crispr's Gene-Edited Therapy, Endra To Offer Shares

Financial news for CYTR dated on 2018-09-20: Stocks Which Set New 52-Week Low Yesterday, September 19th

Financial news for CYTR dated on 2018-09-13: CytRx Corporation Announces Receipt of Milestone Payment from Orphazyme A/S For \$250K

Financial news for CYTR dated on 2018-09-12: Stocks Which Set New 52-Week Low Yesterday, September 11th

Financial news for CYTR dated on 2018-08-17: Stocks Which Set New 52-Week Low Yesterday, August 16th

Financial news for CYTR dated on 2018-08-16: Stocks Which Set New 52-Week Low Yesterday, August 15th

Financial news for CYTR dated on 2018-08-06: CytRx Q2 EPS \$(0.10) Beats \$(0.18) Estimate

Financial news for CYTR dated on 2018-07-25: CytRx Reports Centurion BioPharma Filed Provisional Patent Application Covering ACDx For Use Alongside Albumin Binding Ultra-High Potency LADR Drug Candidates

Financial news for CYTR dated on 2018-07-10: Benzinga's Daily Biotech Pulse: Acceleron On Fast Lane, OncoCyte's Accurate Diagnosis, Inspire Medical Gets Aetna Coverage

Financial news for CYTR dated on 2018-06-25: CytRx Joines Russell Microcap Index

Financial news for CYTR dated on 2018-06-21: CytRx Corporation Highlights Review of NantCell Inc's Aldoxorubicin Published in Future Oncology

Financial news for CYTR dated on 2018-06-04: '\$CYTR spinning out its only dubious assets to "enhance value." Better to kick out Steve Kriegsman'

Financial news for CYTR dated on 2018-06-04: CytRx Corporation Launches Centurion BioPharma Corporation to Advance LADR Albumin Binding Ultra-High Potency Oncology Drug Candidates

Financial news for CYTR dated on 2018-05-11: CytRx Shares Down 30.1% After Co. Earlier Priced 5.6M Share Offering At \$1.25/Share

Financial news for CYTR dated on 2018-05-11: CytRx Prices Offering Of 5.6M Shares At \$1.25/Share For Gross Proceeds \$7M

Financial news for CYTR dated on 2018-05-08: CytRx Q1 GAAP EPS \$(0.15) vs GAAP EPS \$(0.60) In Same Qtr. Last Year

Financial news for CYTR dated on 2018-05-03: Benzinga's Top Upgrades, Downgrades For May 3, 2018

Financial news for CYTR dated on 2018-05-03: CytRx Names Eric Curtis Pres, COO

Financial news for CYTR dated on 2018-05-03: H.C. Wainwright Assumes CytRx at Buy, Announces Price Target \$4

Financial news for CYTR dated on 2018-04-18: CytRx Says LADR-7, LADR-8, LADR-9 and LADR-10 Demonstrate Robust Complete and Partial Responses and Long-Term Antitumor Activity in Melanoma, Lung, Breast, Ovarian, Head and Neck and Renal Cell Cancers; Conf. Call Today At 11 a.m.

Financial news for CYTR dated on 2018-03-20: 42 Biggest Movers From Yesterday

Financial news for CYTR dated on 2018-03-19: CytRx Earlier Reported FY17 EPS \$(1.46), Up From \$(3.78) In FY16, Sales \$100K vs \$200k In FY16

Financial news for CYTR dated on 2018-03-19: Earnings Scheduled For March 19, 2018

Financial news for CYTR dated on 2018-03-16: The Week Ahead In Biotech: Earnings, PDUFA Dates And More

Financial news for CYTR dated on 2018-02-28: CytRx Reports Expansion Of Pharma Partnering Activities For LADR Ultra-High Potency Drug Candidates

Financial news for CYTR dated on 2018-02-05: CytRx Corporation Highlights Second NantCell Inc. Clinical Trial Evaluating Immuno-Oncology Agents and Cell-based Therapies in Combination with Aldoxorubicin in Patients with Advanced Squamous Cell Carcinoma

Financial news for CYTR dated on 2018-01-25: 42 Biggest Movers From Yesterday

Financial news for CYTR dated on 2018-01-17: CytRx Reports Dosing Of First Patient In Licensee NantCell Trial For Metastatic Pancreatic Cancer

Financial news for CYTR dated on 2017-12-06: CytRx Corporation Reports Filing of Key Provisional Patent Applications for Ultra-High Potency LADR Drug Candidates

Financial news for CYTR dated on 2017-11-17: Adam Feuerstein Tweets: Two things on \$CYTR: 1. A better investigation would focus on missing aldoxorubicin ph2 study in SCLC. Data were ready in June, but they've been disappeared. 2. Stock price -14% since reverse stock split.

Financial news for CYTR dated on 2017-11-17: Adam Feuerstein Tweets: \$CYTR wants to investigate evil, manipulative short sellers and "erroneous statements from "bloggers." Kriegsman is drowning.

Financial news for CYTR dated on 2017-11-17: CytRx Corporation Regains Nasdaq Listing Compliance

Financial news for CYTR dated on 2017-11-13: Adam Feuerstein Tweets: \$CYTR Suggestion. Firing Kriegsman and clawing back \$Ms he's siphoned from shareholders is better IR strategy than PR, PR, PR...

Financial news for CYTR dated on 2017-11-08: CytRx Reports Q3 EPS \$(0.19) vs \$(0.80) In Prior Year Period

Financial news for CYTR dated on 2017-11-06: UPDATE: CytRx Says Co.'s Drug Development Efforts Will Be Led By Hurley Consulting Associates

Financial news for CYTR dated on 2017-11-06: CytRx Reports Strategic Realignment Of Clinical Development Team

Financial news for CYTR dated on 2017-11-02: UPDATE: CytRx Highlights Co. Goal 'is to Create a New Class of Rationally Designed, Breakthrough Anti-Cancer Drugs'

Financial news for CYTR dated on 2017-11-02: CytRx Offers Update On Recent Progress At Freiburg, Germany Lab; Offers Update For Oncology Pipeline

Financial news for CYTR dated on 2017-10-31: CytRx Corporation Reports 1-For-6 Reverse Stock Split

Financial news for CYTR dated on 2017-10-30: Adam Feuerstein Tweets: His stock has tanked, his drugs have failed, and \$CYTR chief Steve Kriegsman knows who's at fault: Me! [statnews.com/2017/10/30/cyt...](http://statnews.com/2017/10/30/cyt...)

Financial news for CYTR dated on 2017-10-12: CytRx Reports Inclusion Of Aldoxorubicin In Pending Upcoming Trial Submissions Planned By Licensee NantCell

Financial news for CYTR dated on 2017-10-04: CytRx Reports ISS Has Recommended Holders Vote 'FOR' Co.'s Reverse Stock Split

Financial news for CYTR dated on 2017-10-02: UPDATE: CytRx 'has been actively working with the NantCell team to transition the aldoxorubicin program, including both completed and ongoing studies'

Financial news for CYTR dated on 2017-10-02: UPDATE: CytRx Ended Q2 With \$55M In Cash, Restructured, Paid Down \$10M Of Existing Debt In Q3

Financial news for CYTR dated on 2017-10-02: CytRx Offers Update, Highlights Future Plans

Financial news for CYTR dated on 2017-09-21: CytRx Reports Glass Lewis Recommends Shareholders Vote 'FOR' Proposed Reverse Stock Split

Financial news for CYTR dated on 2017-08-30: CytRx Reports Filing Of Definitive Proxy Statement Related To Upcoming Special Meeting

Financial news for CYTR dated on 2017-08-24: CytRx Corporation Reports Receipt of NASDAQ Listing Determination Indicating Failure To Regain Compliance With NASDAQ \$1.00 Bid Price Requirement

Financial news for CYTR dated on 2017-08-03: CytRx Reports Q2 EPS \$(0.10) vs \$(0.27) In Prior Year Period

Financial news for CYTR dated on 2017-07-28: CytRx Shares To Resume Trade At 9:50 p.m. EDT

Financial news for CYTR dated on 2017-07-28: STAT News Adam Feuerstein '\$CYTR -- It's a puddly \$13M licensing deal w/ Nantworks. Rest is hope and prayer. Kriegsman and Soon-Shiong deserve each other.'

Financial news for CYTR dated on 2017-07-28: UPDATE: As Part Of Licensing Agreement, NantCell Made Strategic Investment Purchasing \$13M Shares Of CYTR At \$1.10/Share, CYTR Entitled To Add'l \$343M In Milestone Pymts.

Financial news for CYTR dated on 2017-07-28: CytRx Corporation Reports Global Strategic License With NantCell Inc. For Aldoxorubicin

Financial news for CYTR dated on 2017-07-28: CytRx Shares Halted, News Pending

Financial news for CYTR dated on 2017-06-30: Clinical Data Expected Today From Achillion Pharma, CytRX, and Valeant Pharma

Financial news for CYTR dated on 2017-06-13: CytRx Chief Operating and Medical Officer Dr. Daniel Levitt To Step Down June 30th

Financial news for CYTR dated on 2017-06-08: CytRx Offers Update On Regulatory Pathway For Aldoxorubicin In Soft Tissue Sarcomas: Says Current Clinical, Preclinical Data Can Support Approval

Financial news for CYTR dated on 2017-06-01: Biotech Expert Adam Feuerstein Tweets 'I imagine \$CYTR will spin heavily and we will all laugh. Going for approval and receiving approval vastly different things. Latter unlikely.'

Financial news for CYTR dated on 2017-05-30: Option Alert: Cytrx Sep 2.0 Calls Sweep: 800 @ ASK \$0.10: 1173 traded vs 2156 OI: Earnings 8/8 Before Open (est) \$0.80 Ref

Financial news for CYTR dated on 2017-05-25: Volume Spike in Cytrx

Financial news for CYTR dated on 2017-05-19: The Most Notable Abstracts Released

Ahead Of ASCO 2017

Financial news for CYTR dated on 2017-05-18: 15 Biggest Mid-Day Gainers For Thursday

Financial news for CYTR dated on 2017-05-17: CytRx Says Results from Phase 3 Aldoxorubicin Data in Patients with Soft Tissue Sarcomas 'Continue to Demonstrate Significantly Prolonged PFS in North American and L-sarcoma Patients Compared to Standard Treatments'

Financial news for CYTR dated on 2017-05-10: CytRx Reports Q1 EPS \$(0.10)

Financial news for CYTR dated on 2017-05-01: Sabby Management Reports 7.36% Stake In CytRx

Financial news for CYTR dated on 2017-04-28: CytRx Prices \$30M Share Offering At \$0.50/Share

Financial news for CYTR dated on 2017-04-27: Cytrx Files for Stock Offering

Financial news for CYTR dated on 2017-04-27: Adam Feuerstein Tweets: The \$CYTR banker is H.C. Wainwright. Naturally.

Financial news for CYTR dated on 2017-04-27: Adam Feuerstein Tweets: \$CYTR offering in the works, sources tell me. Seeking to raise \$20-30M at discount to market. Trying to price tonight.

Financial news for CYTR dated on 2017-04-19: CytRx Reports FDA Deal on Regulatory Pathway to Approve Aldoxorubicin in Soft Tissue Sarcomas

Financial news for CYTR dated on 2017-04-11: Adam Feuerstein Tweets: \$CYTR hired a promoter in 2014 to write fake articles, pump the stock IN FRONT OF a \$75M stock offering! thestreet.com/story/14082476...

Financial news for CYTR dated on 2017-04-11: Adam Feuerstein Tweets: For These Small-Cap Biotech CEOs, Stock Promotion, not Drug Development, was Priority No. 1 --> thestreet.com/story/14082476... \$AVXL \$CYTR \$ONCS

Financial news for CYTR dated on 2017-04-10: Adam Feuerstein Tweets: Of all biotech cos. targeted by SEC today in stock-promotion crackdown, only \$CYTR CEO Steve Kriegsman still retains job. That shouldn't be.

Financial news for CYTR dated on 2017-04-10: Adam Feuerstein Tweets: Today is a very good day. Gratifying to see SEC take action against paid stock promotions at \$GALE \$CYTR sec.gov/news/press-rel...

Financial news for CYTR dated on 2017-03-20: EU Told By Britain it Will Announce Monday it Will Trigger Art.50 Exit Clause on March 29 -Reuters

Financial news for CYTR dated on 2017-03-16: Adam Feuerstein Tweets: In new 10-K, \$CYTR disclose 3 deaths due to aldoxorubicin in failed ph3 sarcoma trial vs. 0 in control arm. Previously, said 1 v. 0 deaths.

Financial news for CYTR dated on 2017-03-15: CytRx Reports FY16 EPS (0.63) vs. \$(0.70) Est., Sales \$200K vs. \$100k Est.

Financial news for CYTR dated on 2017-02-13: Bio CEO & Investor Conference Begins Today; Presenters Include Inovio Pharmaceuticals, Agile Therapeutics, CytRx, Eiger Biopharmaceuticals, Neurotrope, & Ocular Therapeutix

Financial news for CYTR dated on 2017-01-04: Cytrx Granted Type B Pre-NDA Meeting With U.S. FDA For Registration Pathway With Aldoxorubicin, Expects Overall Survival Data Available In 2017

Financial news for CYTR dated on 2016-12-30: Cytori Files for up to 6.51M Share Offering

Financial news for CYTR dated on 2016-12-23: 6 Worst Biotech Stocks Of 2016

Financial news for CYTR dated on 2016-12-22: S-3 from CytRx Shows Registration for \$200M Mixed Securities Shelf Offering

Financial news for CYTR dated on 2016-12-19: CytRx Announces Daniel Levitt COO

Financial news for CYTR dated on 2016-12-13: CytRx Corporation Announces \$8.1 Million Registered Direct Offering of Common Stock

Financial news for CYTR dated on 2016-12-13: Watch These 4 Huge Put Purchases In Tuesday Trade

Financial news for CYTR dated on 2016-12-12: Option Alert: CYTR Decl6 0.5 Puts Sweep: 500 @ ASK \$0.05: 500 traded vs 460 OI: Earnings 3/9 After Close (est) \$0.51 Ref

Financial news for CYTR dated on 2016-11-29: CombiMatrix's Pre-Implantation Genetic Screening Approval Highlights Today's Pre-Market Biotech Roundup

Financial news for CYTR dated on 2016-11-29: Adam Feuerstein Tweets: \$CYTR CEO Pockets Millions of Dollars as Failed Sarcoma Drug Moves to FDA  
thetstreet.com/story/13907339... You know how this story ends.

Financial news for CYTR dated on 2016-11-29: Cytrx +51.79% Premarket @\$0.85; Co Announced Aldoxorubicin Achieved Primary Endpoint Of Statistically Significant Improvement In Progression-free Survival In Patients With Liposarcoma

Financial news for CYTR dated on 2016-11-29: UPDATE: Cytrx Expects to Submit NDA With FDA for Aldoxorubicin as Treatment for Patients With Relapsed or Refractory STS in 2017

Financial news for CYTR dated on 2016-11-29: Cytrx Corp Reports Aldoxorubicin Achieves Primary Endpoint Of Statistically Significant Improvement In Progression-free Survival In Patients With Liposarcoma

Financial news for CYTR dated on 2016-11-11: CytRx Presents Positive Interim Results from On-going Phase 1b/2 Aldoxorubicin Combination Clinical Trial at the 2016 CTOS Annual Meeting

Financial news for CYTR dated on 2016-11-09: CytRx Reports Q3 EPS \$(0.13), Inline

Financial news for CYTR dated on 2016-10-10: CytRx Reports On-going Aldoxorubicin Plus Ifosfamide/Mesna Combination Shows Objective Responses And Stable Disease In 35 of 36 Patients

Financial news for CYTR dated on 2016-07-29: CytRx Reports Q2 EPS \$(0.27) vs. Est. \$(0.19)

Financial news for CYTR dated on 2016-07-15: Mid-Afternoon Market Update: Infosys Shares Decline Following Disappointing Q1 Results; Herbalife Shares Spike Higher

Financial news for CYTR dated on 2016-07-15: 10 Biggest Mid-Day Losers For Friday

Financial news for CYTR dated on 2016-07-15: Mid-Day Market Update: U.S. Stocks Turn Lower; Iteris Shares Climb Following Q1 Sales Outlook

Financial news for CYTR dated on 2016-07-15: Stocks Hitting 52-Week Lows

Financial news for CYTR dated on 2016-07-15: Mid-Morning Market Update: Markets Open Higher; Wells Fargo Earnings Meet Estimates

Financial news for CYTR dated on 2016-07-15: 12 Stocks Moving In Friday's Pre-Market Session

Financial news for CYTR dated on 2016-07-15: A Peek Into The Markets: U.S. Stock Futures Edge Higher Ahead Of Bank Earnings

Financial news for CYTR dated on 2016-07-15: CytRx Prices 28.6M Share Offering At \$0.70/Share

Financial news for CYTR dated on 2016-07-15: CytRx -25% Premarket; Co Announced Proposed Offering of Common Stock on Thursday

Financial news for CYTR dated on 2016-07-12: Mid-Afternoon Market Update: Dow Jumps 140 Points; Imperva Shares Slide Following Reduced Q2 Outlook

Financial news for CYTR dated on 2016-07-12: 8 Biggest Mid-Day Losers For Tuesday

Financial news for CYTR dated on 2016-07-12: Mid-Day Market Update: Crude Oil Up 3%; Seagate Shares Surge On Strong Revenue Guidance

Financial news for CYTR dated on 2016-07-12: Stocks Hitting 52-Week Lows

Financial news for CYTR dated on 2016-07-12: Mid-Morning Market Update: Markets Open Higher; Alcoa Profit Beats Expectations

Financial news for CYTR dated on 2016-07-12: 15 Stocks Moving In Tuesday's Pre-Market Session

Financial news for CYTR dated on 2016-07-11: UPDATE: CytRx Shares Down 56% After Hours

Financial news for CYTR dated on 2016-07-11: CytRx Shares Resume, Moving Sharply Lower

Financial news for CYTR dated on 2016-07-11: CytRx Shares to Resume Trade at 4:30 p.m. EDT

Financial news for CYTR dated on 2016-07-11: UPDATE: CytRx Corp. Says Current They Will Conduct A 2nd Analysis After Current Evaluation Did Not Show Significant Difference Between Aldoxorubicin and Investigator's Choice Therapy For PFS

Financial news for CYTR dated on 2016-07-11: CytRx Announces Initial Results of Phase 3 Trial of Aldoxorubicin in Patients with Second-Line Soft Tissue Sarcoma; Subsequent Analysis to Be Announced Fourth Quarter 2016

Financial news for CYTR dated on 2016-07-11: CytRx Shares Halted News Pending

Financial news for CYTR dated on 2016-07-11: Option Alert: CYTR Jul16 2.5 Calls Sweep: 700 @ ASK \$0.60: 1727 traded vs 987 OI: Earnings 8/1 \$2.44 Ref

Financial news for CYTR dated on 2016-07-11: Option Alert: CYTR Jul16 4.0 Calls Sweep: 775 @ ASK \$0.15: 2303 traded vs 4351 OI: Earnings 8/1 \$2.31 Ref

Financial news for CYTR dated on 2016-07-11: Option Alert: CYTR Jul16 4.0 Calls Sweep: 1001 @ ASK \$0.15: 1051 traded vs 4351 OI: Earnings 8/1 \$2.32 Ref

Financial news for CYTR dated on 2016-06-30: Option Alert: CYTR Aug16 2.0 Puts Sweep: 781 @ ASK \$0.75: 1048 traded vs 1820 OI: Earnings 8/1 \$2.21 Ref

Financial news for CYTR dated on 2016-06-27: Option Alert: CYTR Aug16 6.0 Calls Sweep: 700 @ ASK \$0.25: 700 traded vs 1285 OI: Earnings 8/1 \$2.13 Ref

Financial news for CYTR dated on 2016-05-27: CytRx Issues ~1.5M Shares for Benefit of Claimants in Matter of In Re CytRx Securities Litigation

Financial news for CYTR dated on 2016-05-11: CytRx Reports Q1 EPS \$(0.19) vs \$(0.26) Est.

Financial news for CYTR dated on 2016-04-04: Mid-Day Market Update: Ruckus Wireless Surges On Acquisition News; Smith & Wesson Shares Slide

Financial news for CYTR dated on 2016-04-04: CytRx Offers Pivotal Phase 3 Trial with Aldoxorubicin Achieved 191 Target Events Triggering Statistical Data Analysis

Financial news for CYTR dated on 2016-03-22: Mid-Morning Market Update: Markets Open Lower; G-III Apparel Misses Q4 Expectations

Financial news for CYTR dated on 2016-03-21: Mid-Day Market Update: Affymetrix Stock Drops; Valeant Shares Spike Higher

Financial news for CYTR dated on 2016-03-21: Mid-Morning Market Update: Markets Edge Lower; Sherwin-Williams To Buy Valspar For \$113/Share

Financial news for CYTR dated on 2016-03-16: Option Alert: CYTR Jun16 3.0 Calls Sweep: 555 @ ASK \$0.40: 555 traded vs 3196 OI: Earnings 5/6 \$2.04 Ref

Financial news for CYTR dated on 2016-03-11: CytRx Reports FY15 EPS (0.97) vs. Prior Year Quarter \$(0.55)

Financial news for CYTR dated on 2016-03-08: CytRx Sells Off to Low of \$2.61 on Volume

Financial news for CYTR dated on 2016-03-07: Option Alert: CYTR Apr16 4.0 Calls Sweep: 1999 @ ASK \$0.10: 1999 traded vs 0 OI: Earnings tmrrw \$3.00 Ref

Financial news for CYTR dated on 2016-01-11: CytRx Names Olivia Ware Chief Commercial Officer

Financial news for CYTR dated on 2016-01-07: Jefferies Initiates Coverage on CytRx at Hold

Financial news for CYTR dated on 2016-01-05: CytRx Announces Settlement of California Stockholder Derivative Lawsuit, Terms Not Disclosed

Financial news for CYTR dated on 2015-12-30: S-3 from CytRx Shows Registration for \$100M Mixed Securities Offering

Financial news for CYTR dated on 2015-12-07: CytRx Reports Nomination of Next Clinical Drug Candidate DK049

Financial news for CYTR dated on 2015-12-01: CytRx Reports Closing of Enrollment for Pivotal Global Phase 3 Trial for Aldoxorubicin Ahead of Schedule

Financial news for CYTR dated on 2015-11-23: CytRx Shares Fall; May be Attributed to Negative Adam F Tweet

Financial news for CYTR dated on 2015-11-23: Aldoxorubicin Continues To Show Positive Clinical Activity In Phase 2 Glioblastoma Trial

Financial news for CYTR dated on 2015-11-23: Aldoxorubicin Continues To Demonstrate Positive Clinical Activity In Phase 2 Glioblastoma Trial

Financial news for CYTR dated on 2015-11-17: Option Alert: \$CYTR Mar \$4 Call Sweep; 878 Contracts @Ask @\$0.30; Ref \$3.18

Financial news for CYTR dated on 2015-11-03: CytRx Corp. Reports Q3 Loss of \$0.11/Share

Financial news for CYTR dated on 2015-11-03: CytRx Corporation Reports Q3 Loss \$0.11 Vs Est Loss \$0.24

Financial news for CYTR dated on 2015-10-28: CytRx to Present Additional Data from its Phase 1b/2 Clinical Trial Combining Aldoxorubicin with Ifosfamide/Mesna at the CTOS 2015 Annual Meeting

Financial news for CYTR dated on 2015-09-21: Mid-Morning Market Update: Markets Open Higher; Lennar Tops Q3 Views

Financial news for CYTR dated on 2015-09-21: Morning Market Gainers

Financial news for CYTR dated on 2015-09-21: UPDATE: CytRx Trial of Aldoxorubicin Showed Primary Endpoint Subjects Had Highly Statistical Significance Above Clinical Outcomes

Financial news for CYTR dated on 2015-09-21: CytRx Announces the Publication of its Positive Global Phase 2b Clinical Trial Results for Soft Tissue Sarcoma in the Peer-Reviewed JAMA Oncology

Financial news for CYTR dated on 2015-09-03: CytRx Announces the Presentation of its Phase 2b Clinical Trial Design in Small Cell Lung Cancer at the World Conference on Lung Cancer in Denver, Colorado

Financial news for CYTR dated on 2015-07-31: Option Alert: Cytrx Dec \$4 Call; 1000 Contracts @Ask @\$0.10

Financial news for CYTR dated on 2015-07-21: Mid-Day Market Update: Dow Dips Over 1%; Harley-Davidson Shares Rise On Earnings Beat

Financial news for CYTR dated on 2015-07-21: Market Update: Tuesday's Market Movers: Labor Departments New Overtime Rules; Earnings Week!

Financial news for CYTR dated on 2015-07-21: Morning Market Losers

Financial news for CYTR dated on 2015-07-21: CytRx Reports Picing Of 9.1M Shares At \$2.75/Share

Financial news for CYTR dated on 2015-07-20: CytRx Reports Proposed Offering; Terms Not Disclosed

Financial news for CYTR dated on 2015-06-29: CytRx Reports Presentation of Interim Phase 2 Data for Aldoxorubicin for HIV-Related Kaposi's Sarcoma

Financial news for CYTR dated on 2015-06-02: CytRx Reports Settlement In Stockholder Derivative Lawsuit

Financial news for CYTR dated on 2015-05-27: CytRx to Showcase Aldoxorubicin Clinical Data at the 2015 ASCO Annual Meeting

Financial news for CYTR dated on 2015-05-21: CytRx Reports Positive Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme (Brain Cancer)

Financial news for CYTR dated on 2015-05-21: CytRx Announces Encouraging Updated Phase 2 Aldoxorubicin Clinical Trial Results in Glioblastoma Multiforme

Financial news for CYTR dated on 2015-05-05: This Is A Near-Term Driver At Cytrx

Financial news for CYTR dated on 2015-05-04: CytRx Announces Aldoxorubicin Has Demonstrated Both Tumor Shrinkage, Improved Quality of Life in Chemotherapy-Resistant Cancers



Financial news for CYTR dated on 2015-05-01: CytRx Reports Q1 Loss of \$0.31/Share

Financial news for CYTR dated on 2015-04-21: FBR Capital Initiates Coverage on CytRx at Outperform, Announces \$8.00 PT

Financial news for CYTR dated on 2015-04-20: Pharmacological Advancements in Neuroscience Drug Discovery & Pre-Clinical Studies for Fragile X Syndrome to Identify Drug Candidates for Autism Therapies Lead Biotech Sector Research

Financial news for CYTR dated on 2015-04-17: Oppenheimer Jumps On CytRx Bandwagon

Financial news for CYTR dated on 2015-04-17: Oppenheimer Initiates Coverage on CytRx at Outperform, Announces \$10.00 PT

Financial news for CYTR dated on 2015-01-22: CytRx Reports Total Overall Survival Results from Global Phase 2B Clinical Trial of Aldoxorubicin: Showed 2-Fold Increase in Likelihood of Surviving 2+ Years

Financial news for CYTR dated on 2015-01-20: Tuesday's Morning Movers: FXCM Takes Another Big Drop

Financial news for CYTR dated on 2015-01-20: CytRx Announces FDA's Removal of Partial Clinical Hold for Aldoxorubicin Clinical Trials

Financial news for CYTR dated on 2015-01-08: CytRx Reports Positive Interim Results from Phase 2 Trial of Aldoxorubicin for Treatment of KS: Showed 66% Complete, Partial Responses, No Tumor Progression in Patients

Financial news for CYTR dated on 2015-01-06: Aegis Capital Reiterates Buy On CytRx As Stock Soars 17%

Financial news for CYTR dated on 2015-01-06: Cytrx CEO Says Cautiously Optimistic Regarding Pending FDA Decision on Lifting Partial Clinical Hold on Trials of Cancer Drug Aldoxorubicin; Expects to Hear Back from Agency Later this Month -Reuters

Financial news for CYTR dated on 2015-01-06: Mid-Morning Market Update: Markets Open Higher; Commercial Metals Posts Upbeat Earnings

Financial news for CYTR dated on 2015-01-06: Tuesday's Morning Market Movers: Minerva, El Pollo LoCo And More

Financial news for CYTR dated on 2015-01-06: Morning Market Movers

Financial news for CYTR dated on 2015-01-06: UPDATE: CytRx Shares Rise 17% Premarket on Positive Brain Cancer Study Results

Financial news for CYTR dated on 2015-01-06: CytRx Reports Positive Interim Phase 2 Aldoxorubicin Results in Glioblastoma Multiforme

Financial news for CYTR dated on 2015-01-05: Option Alert: CytRx Jun \$5 Call; 3,051 Contacts Traded vs 226 OI; Currently \$2.88

Financial news for CYTR dated on 2014-12-31: Mid-Morning Market Update: Markets Gain; Pacific Ethanol Reports Merger Deal With Aventine Renewable Energy

Financial news for CYTR dated on 2014-12-03: US Stock Futures Flat; ADP Report In Focus

Financial news for CYTR dated on 2014-12-03: CytRx Receives Written FDA Communication Regarding Partial Clinical Hold for Aldoxorubicin Clinical Trials

Financial news for CYTR dated on 2014-11-18: Morning Market Losers

Financial news for CYTR dated on 2014-11-18: CytRx Reports Partial Clinical Hold from FDA Affecting Aldoxorubicin Clinical Trials

Financial news for CYTR dated on 2014-11-04: CytRx Corporation Reports Q3 EPS of \$(0.10) vs \$(0.25) Est

Financial news for CYTR dated on 2014-11-04: Cytrx Initiated Global Phase 2B Clinical Trial of Aldoxorubicin for Treatment of Relapsed/Refractory Small Cell Lung Cancer

Financial news for CYTR dated on 2014-10-20: CytRx Announces Publication of Phase 1b/2 Aldoxorubicin Clinical Data In Soft Tissue Sarcoma In Cancer, The Peer-Reviewed Journal Of The American Cancer Society

Financial news for CYTR dated on 2014-10-17: CytRx to Present Data from Global Phase 2b Clinical Trial of Aldoxorubicin at CTOS 2104

Financial news for CYTR dated on 2014-10-16: CytRx Names Steven A. Kriegsman as Chairman

Financial news for CYTR dated on 2014-10-13: CytRx Commences Operations at Discovery Laboratory

Financial news for CYTR dated on 2014-10-09: CytRx Initiates Phase 1b Clinical Trial of Aldoxorubicin and Gemcitabine in Patients with Metastatic Solid Tumors

Financial news for CYTR dated on 2014-10-07: CytRx Announces Unexpected Passing Of Chairman Max Link, PhD

Financial news for CYTR dated on 2014-09-30: US Stock Futures Surge Ahead Of Walgreen Earnings, Economic Data

Financial news for CYTR dated on 2014-09-30: CytRx Begins Global Phase 2b Clinical Trial of Aldoxorubicin for Treatment of Relapsed/Refractory Small Cell Lung Cancer

Financial news for CYTR dated on 2014-09-29: CytRx Receives Multiple FDA Orphan Drug Designations for Aldoxorubicin for the Treatment of Glioblastoma, Small Cell Lung Cancer and Ovarian Cancer

Financial news for CYTR dated on 2014-09-26: Shares of CytRx Spike to New Highs as Co. Received Orphan Drug Designation for Aldoxorubicin

Financial news for CYTR dated on 2014-09-22: US Stock Futures Decline Ahead Of Home Sales Report

Financial news for CYTR dated on 2014-09-22: CytRx Aldoxorubicin Global Phase 3 STS and Global Phase 2b Small Cell Lung Cancer Trial Designs to be Presented at ESMO 2014

Financial news for CYTR dated on 2014-09-09: US Stock Futures Flat, Apple In Focus

Financial news for CYTR dated on 2014-09-09: CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Ifosfamide/Mesna as First-Line Treatment in Patients with Advanced Sarcomas

Financial news for CYTR dated on 2014-05-28: CytRx Announces Updated Aldoxorubicin Data from its Global Phase 2b Clinical Trial in First-Line Soft Tissue Sarcoma

Financial news for CYTR dated on 2014-05-05: CytRx Reports Phase 1b/2 Aldoxorubicin Data Supports Ongoing Clinical Development In Soft Tissue Sarcoma

Financial news for CYTR dated on 2014-05-01: Mid-Afternoon Market Update: Markets Turn Back As Meritor Hangs Onto Its Gains

Financial news for CYTR dated on 2014-05-01: Mid-Day Market Update: Weight Watchers Shares Surge On Upbeat Results; JDS Uniphase Tumbles

Financial news for CYTR dated on 2014-05-01: CytRx Reports Q1 EPS of \$0.09 vs \$(0.18) Est; Revenue of \$0.00 vs \$50.0K Est

Financial news for CYTR dated on 2014-04-28: CytRx to Present Completed Phase 1b/2 Progression-Free Survival and Overall Survival Aldoxorubicin Data at R&D Event

Financial news for CYTR dated on 2014-04-24: CytRx to Present Global Phase 2b Trial of Aldoxorubicin in Soft Tissue Sarcomas Data at ASCO

Financial news for CYTR dated on 2014-04-03: Morning Market Movers

Financial news for CYTR dated on 2014-04-03: UPDATE: CytRx Shares Rise 10% Premarket on Positive Aldoxorubicin Data

Financial news for CYTR dated on 2014-04-03: CytRx to Present Updated Aldoxorubicin Preclinical Glioblastoma Data at 2014 AACR Annual Meeting

Financial news for CYTR dated on 2014-03-31: CytRx Receives Orphan Medicinal Product Designation from EC for Aldoxorubicin in Soft Tissue Sarcoma

Financial news for CYTR dated on 2014-03-27: UPDATE: CytRx Says Recent Lawsuits, Negative Publicity Are Without Merit

Financial news for CYTR dated on 2014-03-27: CytRx Issues Statement Regarding Recent Lawsuits

Financial news for CYTR dated on 2014-03-24: CytRx Initiates Pivotal Global Phase 3 Clinical Trial with Aldoxorubicin for Second-Line Treatment of Soft Tissue Sarcoma

Financial news for CYTR dated on 2014-03-18: Adam Feuerstein Tweets: 'Hard to envision \$CYTR escaping SEC investigation now. Tick tock...'

Financial news for CYTR dated on 2014-03-18: Adam Feuerstein Tweet: Hard to envision \$CYTR escaping SEC investigation now. Tick tock

Financial news for CYTR dated on 2014-03-13: Adam Feuerstein Tweet: BREAKING: Richard Pearson has published very important story on stock promotion, focused on \$GALE \$CYTR. Must read --> [seekingalpha.com/article/208617...](http://seekingalpha.com/article/208617...)

Financial news for CYTR dated on 2014-02-05: Cytrx Closes Offering of Shares, Gross Proceeds from 13.225M Shares at \$6.50/Share Were ~\$86M

Financial news for CYTR dated on 2014-01-31: CytrX Shares Plunge as Co. Priced 11.5M Shares at \$6.50/Share; Stock Down 15+%

Financial news for CYTR dated on 2014-01-31: CytrX Prices 11.5M Share Offering at \$6.50/Share

Financial news for CYTR dated on 2014-01-30: CytrX Announces Proposed Public Offering of Common Stock

Financial news for CYTR dated on 2014-01-23: Aegis Capital Maintains Buy on CytrX Corporation, Raises PT to \$12.00

Financial news for CYTR dated on 2014-01-23: CytrX Initiates Phase 2 Clinical Trial with Aldoxorubicin for First-Line Treatment of AIDS-Related Kaposi's Sarcoma

Financial news for CYTR dated on 2014-01-21: CytrX Receives FDA Approval To Extend Aldoxorubicin Dosing Cycles Until Disease Progression In Upcoming Pivotal, Global Phase 3 Trial For Soft Tissue Sarcomas

Financial news for CYTR dated on 2014-01-10: CytrX Spikes Higher

Financial news for CYTR dated on 2014-01-08: CytrX Reports Positive Results from Global Phase 2b Clinical Trial with Aldoxorubicin in Advanced Soft Tissue Sarcomas

Financial news for CYTR dated on 2013-12-31: CytrX Spikes Higher

Financial news for CYTR dated on 2013-12-30: Morning Market Movers

Financial news for CYTR dated on 2013-12-27: Cytrx Shares Spike Higher; May be Attributed to Forbes Article

Financial news for CYTR dated on 2013-12-24: Morning Market Movers

Financial news for CYTR dated on 2013-12-16: Morning Market Losers

Financial news for CYTR dated on 2013-12-11: Stocks Hitting 52-Week Highs

Financial news for CYTR dated on 2013-12-11: Morning Market Movers

Financial news for CYTR dated on 2013-12-11: UPDATE: Cytrx Shares Rise 79% Pre-Market on Positive Phase 2b Data

Financial news for CYTR dated on 2013-12-11: CytrX Reports Highly Statistically Significant Positive Results from Global Phase 2B Clinical Trial

Financial news for CYTR dated on 2013-11-20: CytrX Initiates Phase 2 Aldoxorub Trial in Patients with Unresectable GBM Brain Cancer

Financial news for CYTR dated on 2013-11-19: A Small Cap That is Cashing In on ObamaCare

Financial news for CYTR dated on 2013-10-31: CytrX Announces Further Positive Clinical Data from Global Phase 2b Aldoxorubicin Study

Financial news for CYTR dated on 2013-10-29: CytrX Reports Q3 EPS of \$(0.33) vs \$(0.22) Est; Revenue of \$0.00 vs \$200.0K Est

Financial news for CYTR dated on 2013-10-23: CytrX Says Wins FDA Acceptance for Protocol of Phase 2 Aldoxorubicin in Glioblastoma Trial

Financial news for CYTR dated on 2013-10-16: 3 Small Caps That Should Profit from Obamacare

Financial news for CYTR dated on 2013-10-10: Edison Investment Research Comments on CytrX Corporation Following Positive Aldoxorubicin Data

Financial news for CYTR dated on 2013-10-09: Morning Market Losers

Financial news for CYTR dated on 2013-10-09: Benzinga's Top Pre-Market Losers

Financial news for CYTR dated on 2013-10-09: CytRx Prices 10M Share Offering at \$2.25/Share

Financial news for CYTR dated on 2013-10-09: Stocks To Watch For October 9, 2013

Financial news for CYTR dated on 2013-10-08: CytRx Announces Proposed Public Offering of Common Stock

Financial news for CYTR dated on 2013-09-30: CytRx's Reports Aldoxorubicin Data Demonstrates Advantages over Doxorubicin

Financial news for CYTR dated on 2013-08-06: CytRx Corporation Reports Q2 EPS of \$(0.11) vs \$(0.19) Est; Revenue of \$200.0K

Financial news for CYTR dated on 2013-07-09: Afternoon Market Gainers

Financial news for CYTR dated on 2013-07-09: Morning Market Movers

Financial news for CYTR dated on 2013-07-09: Adam Feuerstein Tweets Cytrx Up 40% because a Me-Too Version of Generic Doxorubicin Shrank Mice Brain Tumors

Financial news for CYTR dated on 2013-07-09: CytRx's Aldoxorubicin Shrinks Tumors, Prolongs Survival in Model of Human Brain Cancer

Financial news for CYTR dated on 2013-06-24: CytRx Reaches Enrollment Target in International Phase 2b Clinical Trial with Aldoxorubicin as First-Line Treatment for Soft Tissue Sarcoma

Financial news for CYTR dated on 2013-06-19: UPDATE: Aegis Capital Lowers PT on CytRx on Continued Aldoxorubicin Trial Results

Financial news for CYTR dated on 2013-06-03: CytRx Wins Favorable Novel Combination of Aldoxorubicin-Doxorubicin

Financial news for CYTR dated on 2013-05-31: Roth Capital Reinstates Buy on CytRx Corporation, Announces \$9.00 T

Financial news for CYTR dated on 2013-05-21: CytRx Offers Initial Results from Trial with Aldoxorubicin in Solid Tumors

Financial news for CYTR dated on 2013-05-20: CytRx Offers Letter to Holders, Gives Business Update

Financial news for CYTR dated on 2013-05-08: CytRx Provides Update on Clinical Programs

Financial news for CYTR dated on 2013-05-06: CytRx Receives Recommendation from Data Safety Monitoring Committee to complete International Phase 2b Trial with Aldoxorubicin

Financial news for CYTR dated on 2013-04-25: UPDATE: Edison Investment Research Raises PT on CytRx on FDA Aldoxorubicin Agreement

Financial news for CYTR dated on 2013-04-23: CytRx Announces Agreement with FDA on Special Protocol Assessment for Global Pivotal Phase 3 Clinical Trial with Aldoxorubicin for Soft Tissue Sarcoma

Financial news for CYTR dated on 2013-03-11: CytRx Corporation Reports FY12 EPS of \$(0.78) vs \$(1.02) Est

Financial news for CYTR dated on 2013-01-31: CytRx Wins Recommendation from DSMC to Complete Phase 2b Trial with Tamibarotene as First-Line Treatment for NSC Lung Cancer

Financial news for CYTR dated on 2012-12-06: Cytrx Files \$100M Mixed Securities Shelf

Financial news for CYTR dated on 2012-11-09: CytRx Reports Q3 EPS \$0.07 vs \$-0.31 Est

Financial news for CYTR dated on 2012-10-24: CytRx Closes Offering of 9.2M Shares

Financial news for CYTR dated on 2012-10-24: CytRx Announces Closing of 9.2M Share Public Offering of Common Stock

Financial news for CYTR dated on 2012-10-19: CytRx Announces Exercise of Underwriters' Over-Allotment Option

Financial news for CYTR dated on 2012-10-17: CytRx Prices 8M Share Offering at \$2.50/Share

Financial news for CYTR dated on 2012-10-17: CytRx Announces Proposed Public Offering of Common Stock

Financial news for CYTR dated on 2012-10-15: CytRx Starts Open-Label Phase 1B Trial for Aldoxorubicin

Financial news for CYTR dated on 2012-10-15: CytRx Starts Open-Label Phase 1B Trial for Aldoxorubicin

Financial news for CYTR dated on 2012-10-15: CytRx Starts Open-Label Phase 1B Trial for Aldoxorubicin

Financial news for CYTR dated on 2012-10-15: CytRx Starts Open-Label Phase 1B Trial for Aldoxorubicin

Financial news for CYTR dated on 2012-10-01: CytRx's Aldoxorubicin Clinical Data Presented at the ESMO 2012 Congress

Financial news for CYTR dated on 2012-09-10: Benzinga's Top Initiations

Financial news for CYTR dated on 2012-09-10: UPDATE: Rodman & Renshaw Initiates CytRx Corporation at Buy

Financial news for CYTR dated on 2012-09-10: Rodman & Renshaw Initiates Coverage on CytRx at Market Outperform, Announces PT of \$7

Financial news for CYTR dated on 2012-08-09: CytRx Reports Q2 EPS \$-0.63 May Not Compare to \$-0.30 Est

Financial news for CYTR dated on 2012-07-25: CytRx Initiates Phase 1b Clinical Trial with Combination of Aldoxorubicin and Doxorubicin in Patients with Advanced Solid Tumors

Financial news for CYTR dated on 2012-07-09: CytRx Announces Allowance of U.S. Patent Application for Tamibarotene Capsule

Financial news for CYTR dated on 2012-07-02: CytRx Announces Issuance of European Patent Covering INNO-206 Linker Technology

Financial news for CYTR dated on 2012-06-25: Major Milestone Achieved in CytRx's Phase 2b Global Clinical Trial with Tamibarotene as a First-Line Treatment

Financial news for CYTR dated on 2012-06-04: From Earlier: CytRx Announces Favorable Results from Phase 1b/2 Clinical Trial with INNO-206

Financial news for CYTR dated on 2012-06-01: CytRx Regains NASDAQ Compliance

Financial news for CYTR dated on 2012-05-15: CytRx Announces Reverse Stock Split; 1-for-7

Financial news for CYTR dated on 2012-04-26: CytRx Initiates Phase 2 Clinical Trial with INNO-206 in Pancreatic Cancer

Financial news for CYTR dated on 2012-04-23: CytRx Receives NASDAQ Extension

Financial news for CYTR dated on 2012-04-23: CytRx Receives NASDAQ Extension

Financial news for CYTR dated on 2012-04-12: CytRx Announces Issuance of Key U.S. Patent Covering INNO-206 Linker Technology

Financial news for CYTR dated on 2012-02-17: CytRx Receives Notification of Non-Compliance with NASDAQ Minimum Bid Requirement

Financial news for CYTR dated on 2012-01-04: Sickie Cell Knocks Out NFL Player. Can these Companies Help?

Financial news for CYTR dated on 2011-12-22: CytRx Initiates International Phase 2b Clinical Trial with INNO-206 in Advanced Soft Tissue Sarcoma

Financial news for CYTR dated on 2011-12-22: CytRx Initiates International Phase 2b Clinical Trial with INNO-206 in Advanced Soft Tissue Sarcoma

Financial news for CYTR dated on 2011-12-12: CytRx Announces the Presentation of Favorable Phase 2 Clinical Results with Bafetinib in Relapsed B-Cell Chronic Lymphocytic

Financial news for CYTR dated on 2011-10-31: CytRx Announces Favorable Initial Results from its Ongoing Phase 1b/2 Clinical Trial in Patients with Soft Tissue Sarcomas

Financial news for CYTR dated on 2011-10-04: CytRx's ENABLE Phase 2 Trial Results with Bafetinib in Relapsed B-Cell Chronic Lymphocytic Leukemia to be Presented at the Prestigious 53rd Annual ASH Meeting

Financial news for CYTR dated on 2011-09-26: CytRx to Substantially Increase Patient Enrollment in INNO-206 Phase 1b/2 Clinical Trial Principally in Patients with Soft Tissue Sarcomas

Financial news for CYTR dated on 2011-08-17: Cytryx to Terminate Pact with Oncotherapeutics

Financial news for CYTR dated on 2011-08-01: CytRx's INNO-206 in Combination Therapy Induces Complete Remissions in Aggressively Growing Ovarian Cancer Tumor Model

Financial news for CYTR dated on 2011-07-27: CytRx Prices \$20.4 Million Public Offering of 39.2M Shares at \$0.52/Share

Financial news for CYTR dated on 2011-07-26: CytRx Announces Public Offering; No Amount Given

Financial news for CYTR dated on 2011-07-06: Biotech/Pharma Stocks Investor News Alert

Financial news for CYTR dated on 2011-07-06: CytRx Announces Safe Administration of High Doses of Doxorubicin with Its Tumor-Targeted Drug, INNO-206

Financial news for CYTR dated on 2011-07-05: CytRx Receives FDA Orphan Drug Designation for INNO-206 for the Treatment of Soft Tissue Sarcomas

Financial news for CYTR dated on 2011-06-13: CytRx Reports Positive Preliminary Results from ENABLE Phase 2 Clinical Trial with Bafetinib in Patients with Relapsed B-Cell Chronic Lymphocytic Leukemia

Financial news for CYTR dated on 2011-04-28: CytRx's INNO-206 Receives FDA Approval for Orphan Drug (CYTR)

Financial news for CYTR dated on 2011-04-11: CytRx Receives Shares of ADVENTRX Pharmaceuticals in SynthRx Transaction

Financial news for CYTR dated on 2011-03-28: CytRx Announces the Presentation of Bafetinib Study Results at the American Academy for Cancer Research Annual Meeting

Financial news for CYTR dated on 2011-03-17: CytRx Begins Phase 1b Clinical Trial with INNO-206 in Patients with Advanced Solid Tumors

Financial news for CYTR dated on 2011-02-14: CytRx to Receive Shares of ADVENTRX Pharmaceuticals in Exchange for 19% Stake in SynthRx

Financial news for CYTR dated on 2011-02-08: CytRx's Bafetinib Demonstrates Ability to Prevent Cancer-Related Bone Loss

Financial news for CYTR dated on 2011-01-12: CytRx Raises \$7 Million from Sale

Financial news for CYTR dated on 2010-12-08: CytRx Gains Compliance with NASDAQ's Minimum Bid Requirement

Financial news for CYTR dated on 2010-11-02: CytRx Awarded \$735,000 Grant

Financial news for CYTR dated on 2010-07-22: CytRx Eliminates Cancer in Advanced Acute Promyelocytic Leukemia

Financial news for CYTR dated on 2010-07-19: CytRx Announces Substantial Progress with Its Bafetinib Clinical Trials Program (CYTR)

Financial news for CYTR dated on 2010-05-11: CytRx Upward Momentum Looks to Continue (CYTR)

Financial news for CYTR dated on 2010-05-11: SmarTrend Detects Continued Buying Pressure in Shares of PSS World Medical (PSSI)

Financial news for CYTR dated on 2010-05-11: Emeritus: The Trend Continues Higher (ESC)

Financial news for CYTR dated on 2010-05-11: Mercury General: The Trend Continues Up (MCY)

Financial news for CYTR dated on 2010-05-11: Uptrend Spotted in Shares of Schweitzer-Mauduit International (SWM)

Financial news for CYTR dated on 2010-05-11: SmarTrend's Trend Spotter Sees Continued Upward Momentum on Shares of Amdocs (DOX)

Financial news for CYTR dated on 2010-05-11: Dionex Upward Momentum Looks to Continue (DNEX)

Financial news for CYTR dated on 2010-05-11: SmarTrend Detects Continued Buying Pressure in Shares of Iberiabank (IBKC)

Financial news for CYTR dated on 2010-05-11: eResearchTechnology: The Trend Continues Higher (ERES)

Financial news for CYTR dated on 2010-05-11: Look for Shares of Evolution Solar to Rebound after Yesterday's 18.33% Sell Off (EVS0)

Financial news for CYTR dated on 2010-05-11: Corn Products International: The Trend Continues Up (CPO)

Financial news for CYTR dated on 2010-05-11: Intelli-Check - Mobilisa Set to Rebound after Yesterday's Selloff of 3.85% (IDN)

Financial news for CYTR dated on 2010-05-11: After Yesterday's Rally of 7.20%, Connacher Oil and Gas Shares Could Pullback (CLLZF)

Financial news for CYTR dated on 2010-05-11: Watch for Bank of Florida to Rebound after Falling 8.97% Yesterday (BOFL)

Financial news for CYTR dated on 2010-05-11: SmarTrend Watching for Pullback in Shares of Alexza Pharmaceuticals After 0.59% Gain (ALXA)

Financial news for CYTR dated on 2010-05-11: Uptrend Spotted in Shares of Willis Group (WSH)

Financial news for CYTR dated on 2010-05-11: Star Gas Partners Rises 0.94% on Heavy Volume: Watch For Pullback (SGU)

Financial news for CYTR dated on 2010-05-11: Look for Shares of The Inventure Group to Pullback after Yesterday's 5.63% Rise (SNAK)

Financial news for CYTR dated on 2010-05-11: FalconStor Software Set to Rebound after Yesterday's Selloff of 0.70% (FALC)

Financial news for CYTR dated on 2010-05-11: After Yesterday's Rally of 1.75%, MFS Government Markets Income Trust Shares Could Pullback (MGF)

Financial news for CYTR dated on 2010-05-11: SmarTrend Watching for Rebound in Shares of PRG-Schultz International After 1.62% Loss (PRGX)

Financial news for CYTR dated on 2010-05-11: SmarTrend's Trend Spotter Sees Continued Upward Momentum on Shares of Coinstar (CSTR)

Financial news for CYTR dated on 2010-05-11: Watch for TCW Strategic Income Fund to Pullback after Gaining 0.63% Yesterday (TSI)

Financial news for CYTR dated on 2010-05-11: Arrowhead Research Rises 4.65% on Heavy Volume: Watch For Pullback (ARWR)

Financial news for CYTR dated on 2010-05-11: Look for Shares of Uranium Resources to Rebound after Yesterday's 6.90% Sell Off (URRE)

Financial news for CYTR dated on 2010-05-11: After Yesterday's Decline of 9.15%, iGo Offers Investors Better Value (IGOI)

Financial news for CYTR dated on 2010-05-11: Princeton Review Set to Rebound after Yesterday's Selloff of 0.72% (REVU)

Financial news for CYTR dated on 2010-05-11: SmarTrend Watching for Pullback in Shares of Columbia Laboratories After 9.71% Gain (CBRX)

Financial news for CYTR dated on 2010-05-11: Watch for Dreyfus Strategic Municipals to Pullback after Gaining 0.12% Yesterday (LEO)

Financial news for CYTR dated on 2010-05-11: StarTek Falls 2.61% on Heavy Volume: Watch For Rebound (SRT)

Financial news for CYTR dated on 2010-05-11: After Yesterday's Rally of 7.39%, Arbor Realty Trust Shares Could Pullback (ABR)

Financial news for CYTR dated on 2010-05-11: Look for Shares of BlackRock High Income Shares to Pullback after Yesterday's 2.31% Rise (HIS)

Financial news for CYTR dated on 2010-05-11: Watch for Dice Holdings to Pullback after Gaining 4.66% Yesterday (DHX)

Financial news for CYTR dated on 2010-05-11: Premiere Global Services Set to Pullback after Yesterday's Rally of 3.04% (PGI)

Financial news for CYTR dated on 2010-05-11: Obagi Medical Products Rises 2.83% on Heavy Volume: Watch For Pullback (OMPI)

Financial news for CYTR dated on 2010-05-11: SmarTrend Watching for Pullback in Shares of Symyx Technologies After 4.52% Gain (SMMX)

Financial news for CYTR dated on 2010-05-11: After Yesterday's Decline of 1.98%, Cypress Bioscience Offers Investors Better Value (CYPB)

Financial news for CYTR dated on 2010-05-11: Look for Shares of Unifi to Pullback after Yesterday's 8.20% Rise (UFI)

Financial news for CYTR dated on 2010-05-11: BlackRock Income Trust Set to Pullback after Yesterday's Rally of 0.31% (BKT)

Financial news for CYTR dated on 2010-05-11: SmarTrend Watching for Pullback in Shares of PMA Capital After 3.69% Gain (PMACA)

Financial news for CYTR dated on 2010-05-11: Watch for Einstein Noah Restaurant Group to Pullback after Gaining 2.11% Yesterday (BAGL)

Financial news for CYTR dated on 2010-05-11: Look for Shares of Center Financial to Pullback after Yesterday's 4.89% Rise (CLFC)

Financial news for CYTR dated on 2010-05-11: Pike Electric Rises 4.90% on Heavy Volume: Watch For Pullback (PIKE)

Financial news for CYTR dated on 2010-05-11: After Yesterday's Rally of 3.43%, Centerstate Banks of Florida Shares Could Pullback (CSFL)

Financial news for CYTR dated on 2010-05-11: SmarTrend Watching for Pullback in Shares of Cumulus Media After 5.65% Gain (CMLS)

Financial news for CYTR dated on 2010-05-11: Watch for 1-800-Flowers.com to Pullback after Gaining 10.98% Yesterday (FLWS)

Financial news for CYTR dated on 2010-05-11: Nuveen Diversified Dividend and Income Fund Set to Pullback after Yesterday's Rally of 3.58% (JDD)

Financial news for CYTR dated on 2010-05-11: Look for Shares of Rural/Metro to Pullback after Yesterday's 5.92% Rise (RURL)

Financial news for CYTR dated on 2010-05-11: Monotype Imaging Holdings Rises 1.01% on Heavy Volume: Watch For Pullback (TYPE)

Financial news for CYTR dated on 2010-05-11: Platinum Group Metals Set to Pullback after Yesterday's Rally of 10.18% (PLG)

Financial news for CYTR dated on 2010-05-11: After Yesterday's Rally of 5.76%, Nuveen Real Estate Income Fund Shares Could Pullback (JRS)

Financial news for CYTR dated on 2010-05-11: SmarTrend Watching for Pullback in Shares of 3SBio After 3.55% Gain (SSRX)

Financial news for CYTR dated on 2010-05-11: Watch for Curis to Pullback after Gaining 8.59% Yesterday (CRIS)

Financial news for CYTR dated on 2010-05-11: Gorman-Rupp Rises 6.91% on Heavy Volume: Watch For Pullback (GRC)

Financial news for CYTR dated on 2009-11-23: Longtop Financial: Using Vertical Option Spreads to Capture the Next Move